KR20230003433A - 유전자에 기반한 염증성 장 질환의 진단 - Google Patents

유전자에 기반한 염증성 장 질환의 진단 Download PDF

Info

Publication number
KR20230003433A
KR20230003433A KR1020227044940A KR20227044940A KR20230003433A KR 20230003433 A KR20230003433 A KR 20230003433A KR 1020227044940 A KR1020227044940 A KR 1020227044940A KR 20227044940 A KR20227044940 A KR 20227044940A KR 20230003433 A KR20230003433 A KR 20230003433A
Authority
KR
South Korea
Prior art keywords
various embodiments
dna
ibd
subject
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227044940A
Other languages
English (en)
Korean (ko)
Inventor
더모트 피 맥거번
달린 리
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60326226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20230003433(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020247019512A priority Critical patent/KR20240095363A/ko
Publication of KR20230003433A publication Critical patent/KR20230003433A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227044940A 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단 Ceased KR20230003433A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247019512A KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662339357P 2016-05-20 2016-05-20
US62/339,357 2016-05-20
PCT/US2017/033625 WO2017201461A1 (en) 2016-05-20 2017-05-19 Diagnosis of inflammatory bowel disease based on genes
KR1020227003985A KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003985A Division KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247019512A Division KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Publications (1)

Publication Number Publication Date
KR20230003433A true KR20230003433A (ko) 2023-01-05

Family

ID=60326226

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227044940A Ceased KR20230003433A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020247019512A Ceased KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227003985A Active KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020187037151A Ceased KR20190016972A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247019512A Ceased KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227003985A Active KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020187037151A Ceased KR20190016972A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Country Status (6)

Country Link
US (2) US11549146B2 (cg-RX-API-DMAC7.html)
EP (1) EP3458466B1 (cg-RX-API-DMAC7.html)
JP (4) JP7475811B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230003433A (cg-RX-API-DMAC7.html)
CN (2) CN109476698B (cg-RX-API-DMAC7.html)
WO (1) WO2017201461A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
KR20230003433A (ko) 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
EP4171632A2 (en) * 2020-06-26 2023-05-03 Pfizer Inc. Methods of treating inflammatory bowel disease with tl1a antibodies
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN115851911B (zh) * 2022-11-25 2025-10-24 南京鼓楼医院 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用
WO2024148218A2 (en) * 2023-01-06 2024-07-11 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443421A (en) 1982-03-16 1984-04-17 Occidental Chemical Corporation Process for removing particulate impurities from aqueous phosphoric acid
EP0191102B1 (en) 1984-08-27 1989-01-04 Toray Industries, Inc. Solid-liquid separating apparatus
US5000850A (en) 1986-09-10 1991-03-19 Engelhard Corporation Apparatus for dewatering an aqueous clay suspension
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
EP1100962A1 (en) 1998-07-25 2001-05-23 AstraZeneca AB Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
JP2004194534A (ja) 2002-12-17 2004-07-15 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患疾患マーカーおよびその利用
JP2007507460A (ja) * 2003-10-06 2007-03-29 ノバルティス アクチエンゲゼルシャフト 炎症性疾患の治療効力と関連している遺伝子多型の使用
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
EP1963534A2 (en) * 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008100913A2 (en) * 2007-02-12 2008-08-21 The Johns Hopkins University Early detection and prognosis of colon cancers
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100055700A1 (en) 2007-02-28 2010-03-04 Cedars-Sinai Medical Center Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
US20150376707A1 (en) 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
WO2011088380A1 (en) 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using fut2 genetic variants to diagnose crohn's disease
US8118175B2 (en) 2007-07-18 2012-02-21 Siemens Industry, Inc. Venting device for a disc filter
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
MX2010005282A (es) 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
KR20160127181A (ko) 2008-08-12 2016-11-02 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
AU2009285644B2 (en) 2008-08-29 2015-08-20 Janssen Biotech, Inc. Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
JP2010088432A (ja) 2008-09-09 2010-04-22 Kansetsu Saisei Kenkyusho:Kk Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
NZ619527A (en) 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
EP2576838A4 (en) * 2010-06-04 2019-05-15 Nestec S.A. METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
WO2012156515A1 (en) 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
EP2812445A2 (en) 2012-02-10 2014-12-17 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
KR20210107176A (ko) * 2013-05-17 2021-08-31 세다르스-신나이 메디칼 센터 크론병과 연관된 tnfsf15와 dcr3의 변이체
NZ717633A (en) * 2013-10-09 2021-07-30 Cedars Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
WO2015138774A1 (en) * 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3286318A2 (en) 2015-04-22 2018-02-28 Mina Therapeutics Limited Sarna compositions and methods of use
MX2018010266A (es) 2016-02-26 2019-03-28 Nanotech Energy Inc Métodos, dispositivos y sistemas para procesamiento de composiciones carbonosas.
KR20230003433A (ko) * 2016-05-20 2023-01-05 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
US20210254056A1 (en) 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
US11675142B2 (en) 2018-12-14 2023-06-13 Fujikura Ltd. Ferrule, fiber-equipped ferrule, and method for manufacturing fiber-equipped ferrule

Also Published As

Publication number Publication date
US11549146B2 (en) 2023-01-10
JP7392020B2 (ja) 2023-12-05
KR20220025122A (ko) 2022-03-03
JP7475811B2 (ja) 2024-04-30
US20230366028A1 (en) 2023-11-16
JP2022095688A (ja) 2022-06-28
US12545959B2 (en) 2026-02-10
KR20240095363A (ko) 2024-06-25
CN109476698A (zh) 2019-03-15
KR102481305B1 (ko) 2022-12-26
EP3458466A4 (en) 2020-03-04
JP2026048696A (ja) 2026-03-17
EP3458466A1 (en) 2019-03-27
CN109476698B (zh) 2023-10-17
WO2017201461A1 (en) 2017-11-23
CN117286238A (zh) 2023-12-26
JP2024037945A (ja) 2024-03-19
US20190194754A1 (en) 2019-06-27
KR20190016972A (ko) 2019-02-19
EP3458466B1 (en) 2024-08-07
JP2019516375A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
KR102481305B1 (ko) 유전자에 기반한 염증성 장 질환의 진단
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102046668B1 (ko) 암 대상자의 예후를 결정하기 위한 방법 및 핵산
CA3119065A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
CA2941594A1 (en) Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CN101687050A (zh) 用于鉴别原发起源不明的癌的起源的方法和材料
KR20110036608A (ko) 유방암 위험도 평가를 위한 유전적 변이
KR20170086027A (ko) 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
AU2023203393A1 (en) Compositions and methods for screening and identifying clinically aggressive prostate cancer
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
JP2003259877A (ja) 肝線維症疾患マーカーおよびその利用
EP1729930A2 (en) Methods for identifying risk of osteoarthritis and treatments thereof
WO2018209358A2 (en) Systemic delivery of polypeptides
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022634A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
KR20170116009A (ko) 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
US20030124536A1 (en) Diagnosis and treatment of vascular disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221221

Application number text: 1020227003985

Filing date: 20220204

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230315

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240116

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230315

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I